000			04232nam a22005655i 4500
001			207052
003			IT-RoAPU
005			20221214233629.0
006			m|||||o||d||||||||
007			cr || ||||||||
008			210729t20132004nju fo d z eng d
019			_a(OCoLC)979746014
020			_a9780691126142 _qprint
020			_a9781400849666 _qPDF
024	7		_a10.1515/9781400849666 _2doi
035			_a(DE-B1597)9781400849666
035			_a(DE-B1597)447363
035			_a(OCoLC)880236676
040			_aDE-B1597 _beng _cDE-B1597 _erda
050		4	_aQH445.2 .R336 2013
072		7	_aSOC002000 _2bisacsh
082	0	4	_a338.7 _a338.76606 _a338.7660609794
084			_aonline - DeGruyter
100	1		_aRabinow, Paul _eautore
245	1	2	_aA Machine to Make a Future : _bBiotech Chronicles / _cPaul Rabinow, Talia Dan-Cohen.
250			_aWith a New afterword by the authors
264		1	_aPrinceton, NJ : _bPrinceton University Press, _c[2013]
264		4	_c©2004
300			_a1 online resource (224 p.) : _b8 halftones.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0	0	_tFrontmatter -- _tContents -- _tOverture. A MACHINE TO MAKE A FUTURE -- _tChapter One. ENDING AND BEGINNING -- _tChapter Two. THE STATE OF THINGS AT CELERA DIAGNOSTICS, EXPLAINED TO INVESTORS AND TO ANTHROPOLOGISTS -- _tChapter Three. THE MACHINERY AND ITS STEWARDS -- _tChapter Four. ETHICAL AND SOCIAL CONSULTANCY -- _tChapter Five. CONFIDENCE AND TRUST -- _tChapter Six. MODELS ORIENT, TECHNOLOGIES PERFORM, SAMPLES SPEAK (OR VICE VERSA) -- _tChapter Seven. SUMMER 2003 -- _tAfterword -- _tIllustrations -- _tAppendix. A CORPORATE HISTORY -- _tNotes -- _tGlossary
506	0		_arestricted access _uhttp://purl.org/coar/access_right/c_16ec _fonline access with authorization _2star
520			_aA Machine to Make a Future represents a remarkably original look at the present and possible future of biotechnology research in the wake of the mapping of the human genome. The central tenet of Celera Diagnostics--the California biotech company whose formative work during 2003 is the focus of the book--is that the emergent knowledge about the genome, with its profound implications for human health, can now be turned into a powerful diagnostic apparatus--one that will yield breakthrough diagnostic and therapeutic products (and, potentially, profit). Celera's efforts--assuming they succeed--may fundamentally reshape the fabric of how health and health care are understood, practiced, and managed. Presenting a series of interviews with all of the key players in Celera Diagnostics, Paul Rabinow and Talia Dan-Cohen open a fascinating window on the complexity of corporate scientific innovation. This marks a radical departure from other books on the biotech industry by chronicling the vicissitudes of a project during a finite time period, in the words of the actors themselves. Ultimately, the authors conclude, Celera Diagnostics is engaged in a future characterized not by geniuses and their celebrated discoveries but by a largely anonymous and widely distributed profusion of data and results--a "machine to make a future." In their new afterword, Rabinow and Dan-Cohen revisit Celera Diagnostics as its mighty machine grinds along, wondering, along with the scientists, "what constitutes success and what constitutes failure?" The pathos of the situation turns on how one poses the question as much as how one answers it.
530			_aIssued also in print.
538			_aMode of access: Internet via World Wide Web.
546			_aIn English.
588	0		_aDescription based on online resource; title from PDF title page (publisher's Web site, viewed 29. Jul 2021)
650		0	_aBiotechnology industries _zCalifornia.
650		0	_aBusiness anthropology.
650		7	_aSOCIAL SCIENCE / Anthropology / General. _2bisacsh
700	1		_aDan-Cohen, Talia _eautore
850			_aIT-RoAPU
856	4	0	_uhttps://doi.org/10.1515/9781400849666
856	4	0	_uhttps://www.degruyter.com/isbn/9781400849666
856	4	2	_3Cover _uhttps://www.degruyter.com/cover/covers/9781400849666.jpg
942			_cEB
999			_c207052 _d207052